Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Methotrexate-Loaded Vesicles for Lung Cancer Leptomeningeal Metastasis
ChiCTR2500108405Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate in bronchial carcinoma, sponsored by Henan Cancer Hospital. Primary endpoints: Objective response rate (ORR) and Maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
methotrexate
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2500108405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108405.